Literature DB >> 27012495

Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD.

Kathleen M Kantak1, Linda P Dwoskin2.   

Abstract

Entities:  

Keywords:  Adolescence; Atomoxetine; Attention Deficit Hyperactivity Disorder; Cocaine; Methylphenidate; Spontaneously Hypertensive Rats; Substance use disorders; d-Amphetamine

Mesh：

Substances：

Year:  2016        PMID： 27012495      PMCID： PMC4864167          DOI： 10.1016/j.pbb.2016.03.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN： 0091-3057            Impact factor:   3.533


× No keyword cloud information.
  36 in total

1.  Strain differences in self-administration of methylphenidate and sucrose pellets in a rat model of attention-deficit hyperactivity disorder.

Authors:  Julie A Marusich; William Travis McCuddy; Joshua S Beckmann; Cassandra D Gipson; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-12       Impact factor: 2.293

Review 2.  Overview of animal models of attention deficit hyperactivity disorder (ADHD).

Authors:  Vivienne Ann Russell
Journal:  Curr Protoc Neurosci       Date:  2011-01

3.  Neuropsychological performance and attention-deficit hyperactivity disorder subtypes and symptom dimensions.

Authors:  Molly A Nikolas; Joel T Nigg
Journal:  Neuropsychology       Date:  2012-11-12       Impact factor: 3.295

4.  Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats.

Authors:  A C Meyer; S Rahman; R J Charnigo; L P Dwoskin; J C Crabbe; M T Bardo
Journal:  Genes Brain Behav       Date:  2010-08-16       Impact factor: 3.449

5.  Methylphenidate self-administration and conditioned place preference in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.

Authors:  Ike C dela Peńa; Hyung Seok Ahn; Ji Young Choi; Chan Young Shin; Jong Hoon Ryu; Jae Hoon Cheong
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

6.  Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function.

Authors:  Roxann C Harvey; Sucharita Sen; Agripina Deaciuc; Linda P Dwoskin; Kathleen M Kantak
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

Review 7.  Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

Authors:  Steve S Lee; Kathryn L Humphreys; Kate Flory; Rebecca Liu; Kerrie Glass
Journal:  Clin Psychol Rev       Date:  2011-01-20

8.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

9.  Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.

Authors:  Roxann C Harvey; Chloe J Jordan; David H Tassin; Kayla R Moody; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2013-01-31       Impact factor: 3.332

10.  Genetic factors control nicotine self-administration in isogenic adolescent rat strains.

Authors:  Hao Chen; Katie A Hiler; Elizabeth A Tolley; Shannon G Matta; Burt M Sharp
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240
View more
  3 in total

1.  Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study.

Authors:  Brooke S G Molina; Andrea L Howard; James M Swanson; Annamarie Stehli; John T Mitchell; Traci M Kennedy; Jeffery N Epstein; L Eugene Arnold; Lily Hechtman; Benedetto Vitiello; Betsy Hoza
Journal:  J Child Psychol Psychiatry       Date:  2018-01-08       Impact factor: 8.982

Review 2.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

3.  ADHD Medication and Substance-Related Problems.

Authors:  Patrick D Quinn; Zheng Chang; Kwan Hur; Robert D Gibbons; Benjamin B Lahey; Martin E Rickert; Arvid Sjölander; Paul Lichtenstein; Henrik Larsson; Brian M D'Onofrio
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.